PRESS RELEASE | Statement from the Minister for Health on HSE approval of reimbursement of Skyclarys for patients with Friedreich’s Ataxia

On 25 August 2026 the Minister for Health announced that the Health Service Executive has approved reimbursement of the drug Skyclarys for patients with Friedreich’s Ataxia. The decision, made after a statutory review, is expected to bring relief to those living with the rare neuro‑degenerative condition and their families across Ireland, including in Co Cork. The minister said the approval comes at a time when uncertainty about the disease’s future is high and that science and the rule of law must guide such decisions. He thanked the HSE scientists and commercial team for their continued engagement, the manufacturer for intensive recent discussions, the patients for sharing their lived experiences, and the clinicians who advised the HSE senior management team. The minister noted that the HSE will now work with the company to establish the process that will allow patients to access the medication. He asked that this work commence immediately. The announcement was issued through a press release by the Minister for Health, highlighting the importance of independent, expert‑led processes in determining drug reimbursement. The decision is expected to improve access to treatment for those affected by Friedreich’s Ataxia in Co Cork and beyond. For full details, see the Minister for Health press release on the HSE approval of Skyclarys reimbursement.

Summary written by localnews.ie from the original source coverage. Click through for the full report.